Tag: Diagnostics
Apollo Cancer Centres launches ‘End-O Check’ – an early screening &...
End-O Check will provide risk-based assessments, diagnostic testing, and symptom evaluation for women, particularly those in the postmenopausal age group
Thyrocare’s Rahul Guha additionally appointed as MD & CEO of API...
Will continue to lead Thyrocare Technologies in his current role as MD & CEO
Fortis and Agilus expand rapid genomic testing capabilities with launch of...
The Genexus platform enables Next-Generation Sequencing (NGS) with an unparalleled turnaround time - delivering crucial results such as Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and MRD testing within 5 days
NATHEALTH whitepaper flags 85 compliance hurdles; Calls for single-window system &...
Industry-backed whitepaper urges digital-first, harmonised regulation to reduce compliance burden, boost innovation, and enhance patient care
Cipla announces investment in iCaltech Innovations to strengthen respiratory play
Deepens commitment to enhance access to advanced respiratory diagnostic solutions
Max Lab expands to Bengaluru through strategic partnership with Stepcare
The collaboration integrates cutting-edge diagnostic technology with patient-centric clinical care, offering a seamless healthcare experience
DKMS Foundation India to offer free HLA Typing in Punjab under...
The program will prioritise remote and underserved areas, expanding awareness about DKMS Foundation India’s mission, its cause, and its thalassemia program
MedGenome raises Series E funding to expand access to its genomics...
This funding will enable the company to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets
Agilus Diagnostics launches Anti-MCV antibody test in collaboration with Sebia to...
The test detects autoantibodies against a mutated form of the vimentin protein, commonly found in the synovial fluid of RA patients
Waters to merge with BD’s Biosciences & Diagnostics unit in a...
Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion